{"groups":[{"description":"Patients receive trametinib orally PO QD (once daily) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nTrametinib: Given PO\n\nUprosertib: Given PO","id":"FG000","title":"Treatment (Trametinib, Akt Inhibitor GSK2141795)"}],"periods":[{"milestones":[{"achievements":[{"comment":"Includes pts receiving Single agent Trametinib and pts who are receiving Trametinib with AKT Inhibitor GSK2141795","groupId":"FG000","numSubjects":"25"}],"type":"STARTED"},{"achievements":[{"comment":"Patients with progressive disease or who achieve less than PR after 4 courses also received Akt inhibitor GSK2141795 PO daily on days 1-28 along with Tremetinib","groupId":"FG000","numSubjects":"12"}],"type":"Dual Therapy With Trametinib and GSK2141795"},{"achievements":[{"comment":"Note: 25 patients enrolled, however, one patient unevaluable was not included in analysis","groupId":"FG000","numSubjects":"25"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}